Home › Funds › Novo Holdings A/S › PCVX
Novo Holdings A/S position in PCVX
VAXCYTE INC · Health Care
Novo Holdings A/S reported holding 710,000 shares of PCVX (VAXCYTE INC) in its Q3 2026 13F filing — a position valued at US$40.4M, representing 2.71% of its reported portfolio and ranking #11 among its reported holdings. Novo Holdings A/S has disclosed PCVX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Novo Holdings A/S's PCVX position evolved
Novo Holdings A/S first disclosed a stake in PCVX in Q3 2023 at 845,000 shares (US$43.1M). The position peaked in Q3 2024 at 750,000 shares, worth US$85.7M. Across 13 filings, Novo Holdings A/S increased the stake 2 time(s), trimmed it 4 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 710,000 shares valued at US$40.4M — a reduction of -90,000 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 845.00K | $43.08M | New |
| Q4 2023 | 845.00K | $53.07M | Hold |
| Q1 2024 | 845.00K | $57.72M | Hold |
| Q2 2024 | 950.00K | $71.73M | Add |
| Q3 2024 | 750.00K | $85.70M | Reduce |
| Q4 2024 | 750.00K | $61.40M | Hold |
| Q1 2025 | 915.00K | $34.55M | Add |
| Q2 2025 | 916.16K | $29.78M | Hold |
| Q3 2025 | 916.16K | $33.00M | Hold |
| Q4 2025 | 916.16K | $42.27M | Hold |
| Q1 2026 | 860.00K | $49.97M | Reduce |
| Q2 2026 | 800.00K | $46.50M | Reduce |
| Q3 2026 | 710.00K | $40.40M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PCVX and 13F data
PCVX (VAXCYTE INC) is a Health Care company. 32 other funds we track also report a position in PCVX — the largest reported positions include Jupiter Topco LLC (US$1.04B), Janus Henderson Group (US$1.02B), T. Rowe Price Investment Management, Inc. (US$813.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PCVX
- Jupiter Topco LLC 17.97M sh · $1.04B · Q2 2026
- Janus Henderson Group 17.92M sh · $1.02B · Q3 2026
- T. Rowe Price Investment Management, Inc. 14.30M sh · $813.67M · Q3 2026
- RA CAPITAL MANAGEMENT, L.P. 11.47M sh · $652.90M · Q3 2026
- Deep Track Capital, LP 3.51M sh · $199.89M · Q3 2026
- WESTFIELD CAPITAL MANAGEMENT CO LP 3.28M sh · $186.60M · Q3 2026
- Kynam Capital Management, LP 2.61M sh · $148.39M · Q3 2026
- Bellevue Group AG 2.32M sh · $132.14M · Q3 2026
- Caligan Partners LP 2.19M sh · $124.53M · Q3 2026
- Paradigm Biocapital Advisors LP 2.14M sh · $121.93M · Q3 2026
- Maverick Capital 1.61M sh · $93.78M · Q2 2026
- Pivotal bioVenture Partners Investment Advisor LLC 1.43M sh · $81.11M · Q3 2026
More on Novo Holdings A/S
FAQ
How long has Novo Holdings A/S held PCVX?
Novo Holdings A/S has disclosed PCVX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Novo Holdings A/S's current position in PCVX?
As of Q3 2026, Novo Holdings A/S holds 710.00K shares of PCVX (VAXCYTE INC), valued at $40.40M, representing 2.71% of its reported portfolio and ranking #11.
Has Novo Holdings A/S been buying or selling PCVX?
In the latest 13F filing (Q3 2026), Novo Holdings A/S reduced its position in PCVX. The position peaked in Q3 2024 at 750.00K shares.
Which other funds hold PCVX?
Other major institutional holders of PCVX include Jupiter Topco LLC, Janus Henderson Group, T. Rowe Price Investment Management, Inc., among 32 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.